Sepsis Caused by Achromobacter Xylosoxidans in a Child with Cystic Fibrosis and Severe Lung Disease

Overview

Journal Am J Case Rep

Specialty General Medicine

Date 2016 Aug 9

PMID 27498677

Authors

Kim Stobbelaar

Kim Van Hoorenbeeck

Monique Lequesne

Jozef De Dooy

Erwin Ho

Erika Vlieghe

Margaretha Ieven

Stijn Verhulst

Affiliations

Soon will be listed here.

Abstract

BACKGROUND Achromobacter xylosoxidans is an aerobic, motile, Gram-negative, opportunistic pathogen that can be responsible for various severe nosocomial and community-acquired infections. It has been found in immunocompromised patients and patients with several other underlying conditions, but the clinical role of this microorganism in cystic fibrosis is unclear. CASE REPORT We describe a case of septic shock caused by A. xylosoxidans in a 10-year-old child with cystic fibrosis and severe lung disease. CONCLUSIONS As the prevalence of A. xylosoxidans in cystic fibrosis patients is rising and patient-to-patient transmission is highly probable, further studies are warranted to determine its role and to document the appropriate treatment strategy for eradication and long-term treatment of this organism.

References

Conway S, Pond M, Bowler I, Smith D, Simmonds E, Joanes D . The chest radiograph in cystic fibrosis: a new scoring system compared with the Chrispin-Norman and Brasfield scores. Thorax. 1994; 49(9):860-2. PMC: 475170. DOI: 10.1136/thx.49.9.860. View

Tan K, Conway S, Brownlee K, Etherington C, Peckham D . Alcaligenes infection in cystic fibrosis. Pediatr Pulmonol. 2002; 34(2):101-4. DOI: 10.1002/ppul.10143. View

De Baets F, Schelstraete P, Van Daele S, Haerynck F, Vaneechoutte M . Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. J Cyst Fibros. 2006; 6(1):75-8. DOI: 10.1016/j.jcf.2006.05.011. View

Duggan J, Goldstein S, Chenoweth C, Kauffman C, Bradley S . Achromobacter xylosoxidans bacteremia: report of four cases and review of the literature. Clin Infect Dis. 1996; 23(3):569-76. DOI: 10.1093/clinids/23.3.569. View

Lambiase A, Catania M, Del Pezzo M, Rossano F, Terlizzi V, Sepe A . Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis. 2011; 30(8):973-80. PMC: 3132409. DOI: 10.1007/s10096-011-1182-5. View

Aisenberg G, Rolston K, Safdar A . Bacteremia caused by Achromobacter and Alcaligenes species in 46 patients with cancer (1989-2003). Cancer. 2004; 101(9):2134-40. DOI: 10.1002/cncr.20604. View

Vu-Thien H, Darbord J, Moissenet D, Dulot C, Dufourcq J, Marsol P . Investigation of an outbreak of wound infections due to Alcaligenes xylosoxidans transmitted by chlorhexidine in a burns unit. Eur J Clin Microbiol Infect Dis. 1998; 17(10):724-6. DOI: 10.1007/s100960050168. View

Saiman L, Chen Y, Tabibi S, San Gabriel P, Zhou J, Liu Z . Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. J Clin Microbiol. 2001; 39(11):3942-5. PMC: 88468. DOI: 10.1128/JCM.39.11.3942-3945.2001. View

Pereira F, Ibiapina C, Alvim C, Camargos P, Figueiredo R, Pedrosa J . Correlation between Bhalla score and spirometry in children and adolescents with cystic fibrosis. Rev Assoc Med Bras (1992). 2014; 60(3):216-21. DOI: 10.1590/1806-9282.60.03.009. View

10.

Orellana-Peralta F, Jacinto M, Pons M, Gomes C, Bada C, Reyes I . Characterization of two Achromobacter xylosoxidans isolates from patients with pertussis-like symptoms. Asian Pac J Trop Med. 2015; 8(6):464-7. PMC: 7104947. DOI: 10.1016/j.apjtm.2015.05.013. View

11.

Brasfield D, Hicks G, Soong S, TILLER R . The chest roentgenogram in cystic fibrosis: a new scoring system. Pediatrics. 1979; 63(1):24-9. View

12.

Hansen C, Pressler T, Hoiby N, Gormsen M . Chronic infection with Achromobacter xylosoxidans in cystic fibrosis patients; a retrospective case control study. J Cyst Fibros. 2006; 5(4):245-51. DOI: 10.1016/j.jcf.2006.04.002. View

13.

Hansen C, Pressler T, Nielsen K, Jensen P, Bjarnsholt T, Hoiby N . Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. J Cyst Fibros. 2009; 9(1):51-8. DOI: 10.1016/j.jcf.2009.10.005. View

14.

Turel O, Kavuncuoglu S, Hosaf E, Ozbek S, Aldemir E, Uygur T . Bacteremia due to Achromobacter xylosoxidans in neonates: clinical features and outcome. Braz J Infect Dis. 2013; 17(4):450-4. PMC: 9428061. DOI: 10.1016/j.bjid.2013.01.008. View

15.

Stollar F, Adde F, Cunha M, Leone C, Rodrigues J . Shwachman-Kulczycki score still useful to monitor cystic fibrosis severity. Clinics (Sao Paulo). 2011; 66(6):979-83. PMC: 3129961. DOI: 10.1590/s1807-59322011000600010. View